open access
Convulsive status epilepticus management in adults and children: Report of the Working Group of the Polish Society of Epileptology
- Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Warsaw, Poland
- Department of Developmental Neurology, Chair of Neurology, Medical University of Gdansk, Poland
- Centre for Epilepsy Diagnosis and Treatment, Foundation of Epileptology, Warsaw, Poland
- Department of Developmental Neurology, Poznan Univerity of Medical Sciences, Poznań, Poland
- 1st Neurological Department, Institute of Psychiatry and Neurology, Warsaw, Poland
- Department of Anaesthesiology and Intensive Therapy, Medical University of Gdansk, Poland
- Department of Paediatric Anaesthesiology and Intensive Therapy, Poznan University of Medical Sciences, Poznań, Poland
- Clinic of Pediatrics and Neurology of Developmental Age, Medical University of Silesia, Katowice, Poland
- Department of Neurology, Medical University of Lublin, Poland, Poland
- Department of Emeregency Medicine, Medical University of Gdansk, Poland
- Department of Experimental and Clinical Neuropathology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland
open access
Abstract
The Working Group was established at the initiative of the General Board of the Polish Society of Epileptology (PSE) to develop an expert position on the treatment of convulsive status epilepticus (SE) in adults and children in Poland. Generalized convulsive SE is the most common form and also represents the greatest threat to life, highlighting the importance of the choice of appropriate therapeutic treatment.
Aim of guidelineWe present the therapeutic options separately for treatment during the early preclinical (>5–30min), established (30–60min), and refractory (>60min) SE phases. This division is based on time and response to AEDs, and indicates a practical approach based on pathophysiological data.
ResultsBenzodiazepines (BZD) are the first-line drugs. In cases of ineffective first-line treatment and persistence of the seizure, the use of second-line treatment: phenytoin, valproic acid or phenobarbital is required. SE that persists after the administration of benzodiazepines and phenytoin or another second-line AED at appropriate doses is defined as refractory and drug resistant and requires treatment in the intensive care unit (ICU). EEG monitoring is essential during therapy at this stage. Anesthesia is typically continued for an initial period of 24h followed by a slow reversal and is re-established if seizures recur. Anesthesia is usually administered either to the level of the “burst suppression pattern” or to obtain the “EEG suppression” pattern.
ConclusionsExperts agree that close and early cooperation with a neurologist and anesthetist aiming to reduce the risk of pharmacoresistant cases is an extremely important factor in the treatment of patients with SE. This report has educational, practical and organizational aspects, outlining a standard plan for SE management in Poland that will improve therapeutic efficacy.
Abstract
The Working Group was established at the initiative of the General Board of the Polish Society of Epileptology (PSE) to develop an expert position on the treatment of convulsive status epilepticus (SE) in adults and children in Poland. Generalized convulsive SE is the most common form and also represents the greatest threat to life, highlighting the importance of the choice of appropriate therapeutic treatment.
Aim of guidelineWe present the therapeutic options separately for treatment during the early preclinical (>5–30min), established (30–60min), and refractory (>60min) SE phases. This division is based on time and response to AEDs, and indicates a practical approach based on pathophysiological data.
ResultsBenzodiazepines (BZD) are the first-line drugs. In cases of ineffective first-line treatment and persistence of the seizure, the use of second-line treatment: phenytoin, valproic acid or phenobarbital is required. SE that persists after the administration of benzodiazepines and phenytoin or another second-line AED at appropriate doses is defined as refractory and drug resistant and requires treatment in the intensive care unit (ICU). EEG monitoring is essential during therapy at this stage. Anesthesia is typically continued for an initial period of 24h followed by a slow reversal and is re-established if seizures recur. Anesthesia is usually administered either to the level of the “burst suppression pattern” or to obtain the “EEG suppression” pattern.
ConclusionsExperts agree that close and early cooperation with a neurologist and anesthetist aiming to reduce the risk of pharmacoresistant cases is an extremely important factor in the treatment of patients with SE. This report has educational, practical and organizational aspects, outlining a standard plan for SE management in Poland that will improve therapeutic efficacy.
Keywords
Epilepsy, Generalized status epilepticus, Guidelines, EEG
Title
Convulsive status epilepticus management in adults and children: Report of the Working Group of the Polish Society of Epileptology
Journal
Neurologia i Neurochirurgia Polska
Issue
Pages
419-426
Published online
2018-06-13
Page views
758
Article views/downloads
1894
DOI
10.1016/j.pjnns.2018.04.002
Bibliographic record
Neurol Neurochir Pol 2018;52(4):419-426.
Keywords
Epilepsy
Generalized status epilepticus
Guidelines
EEG
Authors
J. Jędrzejczak
M. Mazurkiewicz-Bełdzińska
M. Szmuda
B. Majkowska-Zwolińska
B. Steinborn
D. Ryglewicz
R. Owczuk
A. Bartkowska-Śniatkowska
E. Widera
K. Rejdak
M. Siemiński
E. Nagańska